CR20160199A - Terapia combinada con un anticuerpo anti-ang2 y un agonista de cd40 - Google Patents

Terapia combinada con un anticuerpo anti-ang2 y un agonista de cd40

Info

Publication number
CR20160199A
CR20160199A CR20160199A CR20160199A CR20160199A CR 20160199 A CR20160199 A CR 20160199A CR 20160199 A CR20160199 A CR 20160199A CR 20160199 A CR20160199 A CR 20160199A CR 20160199 A CR20160199 A CR 20160199A
Authority
CR
Costa Rica
Prior art keywords
agonist
combined therapy
ang2 antibody
antibody
ang2
Prior art date
Application number
CR20160199A
Other languages
English (en)
Inventor
Christian Klein
Philipp Mueller
Markus Thomas
Alfred Zippelius
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of CR20160199A publication Critical patent/CR20160199A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/75—Agonist effect on antigen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La presente invención se refiere a la terapia combinada de un anticuerpo que se une a angiopoyetina humana 2 (ANG-2) con un agonista de CD40.
CR20160199A 2013-12-20 2016-04-23 Terapia combinada con un anticuerpo anti-ang2 y un agonista de cd40 CR20160199A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP13198753 2013-12-20
EP14158331 2014-03-07
PCT/EP2014/078233 WO2015091655A1 (en) 2013-12-20 2014-12-17 Combination therapy with an anti-ang2 antibody and a cd40 agonist

Publications (1)

Publication Number Publication Date
CR20160199A true CR20160199A (es) 2016-06-17

Family

ID=52278610

Family Applications (1)

Application Number Title Priority Date Filing Date
CR20160199A CR20160199A (es) 2013-12-20 2016-04-23 Terapia combinada con un anticuerpo anti-ang2 y un agonista de cd40

Country Status (20)

Country Link
US (3) US20150232548A1 (es)
EP (1) EP3082857B1 (es)
JP (1) JP6345787B2 (es)
KR (1) KR20160085888A (es)
CN (1) CN105611944A (es)
AU (1) AU2014368695A1 (es)
BR (1) BR112016007112A2 (es)
CA (1) CA2923591A1 (es)
CL (1) CL2016001586A1 (es)
CR (1) CR20160199A (es)
EA (1) EA201600474A1 (es)
HK (1) HK1221409A1 (es)
IL (1) IL244454A0 (es)
MX (1) MX2016008099A (es)
PE (1) PE20160753A1 (es)
PH (1) PH12016500482A1 (es)
SG (1) SG11201604594SA (es)
TW (1) TWI559931B (es)
WO (1) WO2015091655A1 (es)
ZA (1) ZA201601895B (es)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7658924B2 (en) * 2001-10-11 2010-02-09 Amgen Inc. Angiopoietin-2 specific binding agents
WO2015200905A2 (en) 2014-06-28 2015-12-30 Oligasis, Llc Dual pdgf/vegf antagonists
EP3180087B1 (en) 2014-08-12 2019-03-13 Alligator Bioscience AB Combination therapies with anti cd40 antibodies
SG11201702550WA (en) 2014-11-10 2017-04-27 Hoffmann La Roche ANTI-IL-1beta ANTIBODIES AND METHODS OF USE
JP2017537896A (ja) 2014-11-10 2017-12-21 エフ.ホフマン−ラ ロシュ アーゲーF. Hoffmann−La Roche Aktiengesellschaft 二重特異性抗体及び眼科に使用する方法
WO2016075035A1 (en) * 2014-11-10 2016-05-19 F. Hoffmann-La Roche Ag Anti-ang2 antibodies and methods of use
PE20180315A1 (es) 2015-06-29 2018-02-09 Bristol Myers Squibb Co Anticuerpos para cd40
IL290457B2 (en) 2015-12-30 2025-02-01 Kodiak Sciences Inc Antibodies and their conjugates
US11147819B2 (en) 2016-06-17 2021-10-19 Epizyme, Inc. EZH2 inhibitors for treating cancer
AR113862A1 (es) * 2017-12-01 2020-06-17 Seattle Genetics Inc Anticuerpos anti-cd47 y sus usos para tratar cáncer
CN111788227B (zh) 2017-12-27 2025-02-25 百时美施贵宝公司 抗cd40抗体及其用途
CA3092588A1 (en) 2018-03-02 2019-09-06 Kodiak Sciences Inc. Il-6 antibodies and fusion constructs and conjugates thereof
WO2019241730A2 (en) 2018-06-15 2019-12-19 Flagship Pioneering Innovations V, Inc. Increasing immune activity through modulation of postcellular signaling factors
US11242396B2 (en) * 2018-10-01 2022-02-08 Hoffmann-La Roche Inc. Bispecific antigen binding molecules comprising anti-FAP clone 212
US20220204603A1 (en) * 2019-02-25 2022-06-30 Pharmabcine Inc. Anti-ang2 antibody and use thereof
MA55805A (fr) 2019-05-03 2022-03-09 Flagship Pioneering Innovations V Inc Métodes de modulation de l'activité immunitaire
TWI877179B (zh) * 2019-06-27 2025-03-21 德商百靈佳殷格翰國際股份有限公司 抗-angpt2抗體
CN112168960A (zh) * 2019-07-03 2021-01-05 义慧科技(深圳)有限公司 抗VEGF抗体和抗ANG2抗体在制备治疗具有Ras突变的肿瘤的药物中的应用
EP4027998A1 (en) 2019-09-09 2022-07-20 Basilea Pharmaceutica International AG Pharmaceutical combinations comprising a furazanobenzimidazoles and a cd40 agonist for use in the treatment of neoplastic diseases
CA3157509A1 (en) 2019-10-10 2021-04-15 Kodiak Sciences Inc. Methods of treating an eye disorder
JP2023509359A (ja) 2019-12-17 2023-03-08 フラグシップ パイオニアリング イノベーションズ ブイ,インコーポレーテッド 鉄依存性細胞分解の誘導物質との併用抗癌療法
CN116096906A (zh) 2020-06-29 2023-05-09 旗舰创业创新五公司 工程化以促进萨诺传递的病毒及其在治疗癌症中的用途
TW202241935A (zh) 2020-12-18 2022-11-01 美商世紀治療股份有限公司 具有可調適受體專一性之嵌合抗原受體系統
WO2024151687A1 (en) 2023-01-09 2024-07-18 Flagship Pioneering Innovations V, Inc. Genetic switches and their use in treating cancer
KR20250128899A (ko) * 2024-02-20 2025-08-28 주식회사 맵틱스 Tie2 및 VEGF에 특이적으로 결합하는 이중 특이적 항체 및 이의 용도

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR039067A1 (es) * 2001-11-09 2005-02-09 Pfizer Prod Inc Anticuerpos para cd40
US8268314B2 (en) * 2008-10-08 2012-09-18 Hoffmann-La Roche Inc. Bispecific anti-VEGF/anti-ANG-2 antibodies
US8133979B2 (en) * 2008-12-16 2012-03-13 Hoffmann-La Roche Inc. Antibodies against human angiopoietin 2
TWI426920B (zh) * 2010-03-26 2014-02-21 Hoffmann La Roche 雙專一性、雙價抗-vegf/抗-ang-2抗體
AR090263A1 (es) * 2012-03-08 2014-10-29 Hoffmann La Roche Terapia combinada de anticuerpos contra el csf-1r humano y las utilizaciones de la misma

Also Published As

Publication number Publication date
HK1221409A1 (zh) 2017-06-02
WO2015091655A1 (en) 2015-06-25
CA2923591A1 (en) 2015-06-25
SG11201604594SA (en) 2016-07-28
TWI559931B (en) 2016-12-01
ZA201601895B (en) 2018-11-28
EA201600474A1 (ru) 2016-11-30
AU2014368695A1 (en) 2016-04-14
CN105611944A (zh) 2016-05-25
EP3082857A1 (en) 2016-10-26
EP3082857B1 (en) 2018-07-25
US20180134780A1 (en) 2018-05-17
KR20160085888A (ko) 2016-07-18
JP6345787B2 (ja) 2018-06-20
MX2016008099A (es) 2016-10-13
TW201526915A (zh) 2015-07-16
IL244454A0 (en) 2016-04-21
US20150232548A1 (en) 2015-08-20
PE20160753A1 (es) 2016-08-01
US20200199215A1 (en) 2020-06-25
BR112016007112A2 (pt) 2017-09-19
CL2016001586A1 (es) 2017-05-12
JP2017504600A (ja) 2017-02-09
PH12016500482A1 (en) 2016-05-16

Similar Documents

Publication Publication Date Title
PH12016500482A1 (en) Combination therapy with an anti-ang2 antibody and a cd40 agonist
BR112016000903A2 (pt) anticorpos
DOP2018000181A (es) Terapias de combinación para enfermedades malignas hematológicas con anticuerpos anti-cd38 e inhibidores de survivina
DOP2016000224A (es) Tratamientos combinados con anticuerpos anti-cd38
PH12015501071A1 (en) Combination therapy of anti-her3 antibodies
CL2016000460A1 (es) Proteínas de unión al antígeno gitr
PH12015502565A1 (en) Anti-transferrin receptor antibodies and methods of use
MX2015014500A (es) Terapia de combinacion de anticuerpos contra csf-1r y agonista de tlr9.
UY35399A (es) Conjugados de fármacos con anticuerpos
MX2015012326A (es) Anticuerpos anti-crth2 y su uso.
CR20150247A (es) Anticuerpos de antihemaglutinina y métodos de uso
EA201491357A1 (ru) Анти-lrp5 антитела и способы их применения
TWD165139S (zh) 項鍊
PT2992016T (pt) Terapia de combinação de um anticorpo anti-cd20 afucosilado com um conjugado anticorpo do cd79b-fármaco
BR112015008117A2 (pt) benzamidas
TWD165504S (zh) 錶
UY35463A (es) Formulaciones de polipéptido fc-factor ix.
CO7151478A2 (es) Formulaciones estabilizadas que contienen anticuerpos anti-dll4
AR097668A1 (es) Colorante-polímero
ES2721935T3 (es) Anticuerpos anti-BAG3 para uso terapéutico
CL2015002666A1 (es) Formas de dosificación sólidas de antiemético de liberación prolongada
PH12016501201A1 (en) Synthesis of ent-progesterone and intermediates thereof
TWD166471S (zh) 手錶
BR112015023730A2 (pt) uso de sedoeptulose como suplemento nutricional
MX2015012902A (es) Sintesis de ent-progesterona e intermediarios de la misma.